Search results for " Jan"

showing 10 items of 83 documents

Gozos a nuestra Señora de los Angeles, venerada en la Parroquial Iglesia de la Fidelisima Villa de la Jana por mas de 400 años

El full orlat Grav. xil. enmarcat de la Mare de Déu dels Angels, flanquejat per ornaments florals i situat entre el tít. El text del goig a tres col. separades per filets

Devocions populars La Jana (Comunitat Valenciana)Mare de Déu dels Angels Goigs
researchProduct

Alma Mater: 2012/Pavasaris

2012

Guntars BernātsIlze DimantaErasmus Mundis projektsĶīmijas fakultāteJusts DimantsProjekts "Latvijas sociālā atmiņa un identitāte"atbalsts doktora studijāmBasketbola klubsLU fonda stipendiātiStudentu teātrisUniversitātes Studentu padomeDabaszinātņu un matemātikas izglītības centrsGrāmata "(Divas) puses. Latviešu kara stāsti"Ilgvars Jansons
researchProduct

Zvaigžņotā Debess: 2007, Pavasaris

2007

Latvijas Zinātnes padome, Latvijas Universitāte

Krustvārdu mīklaNeigrundas triecienkrāteris IgaunijāKosmiskais aparāts „Rosetta” – asteroīds SteinsLatvijas Zinātnes padomes ekspertu komisija – AstronomiKosmiskais tūrisms – „SpaceShipTwo”Eiropas astronomi – galaktiku attīstībaSaules aktivitātes cikliUniversāls kalendārsJupitera apriņķošanas periodsRīgas atklātā skolēnu astronomijas olimpiādeBaldones Šmidta teleskopsStarptautiskais Astronomijas gads 2009Zvaigžņotā debess pavasarīMarsa mobilis “Opportunity”Japānas Mēness zonde SELENEGalaktiku pētnieks Agris KalnājsFizikas un astronomijas skolotāja Lilija GrāveElektronikas un datorzinātņu institūts – iekārtas kosmosa pētniecībaiMazā planēta „Vasks”Laika apstākļu modelēšana„Apollo-1” apkalpes traģēdijaProfesors Māris Jansons (1936-1997)LU Astronomiskais tornis – vēstureAstronomijas nometne "Ērgļa Pī"Latvijas atklātā matemātikas olimpiāde – uzdevumiMerkura otrā pāriešana Saules diskam 21.gadsimtāStarptautiskā lāzerlokācijas konferenceMaknota komētaZemes mākslīgie pavadoņi „CubeSat”Baltijas zinātņu vēstures konference Viļņā
researchProduct

Latvijas tautas frontes Augstākās Padomes frakcijas darbība 1991.gada janvārī

2018

Bakalaura darbā aplūkota Latvijas Tautas frontes frakcijas darbība 1991. gada janvārī, analizējot frakcijas ietekmi un nozīmi Latvijas neatkarības atjaunošanā un Latvijas iekšpolitikā un ārpolitikā 1991. gada janvārī. Apskatāmo laika posmu raksturo divvaldības periods. Galvenie varas lēmēji Latvijā bija Latvijas Republikas Augstākā Padome un Ministru Padome, kā arī Padomju Sociālistisko Republiku Savienība. Būtiski saasinājās arī ideoloģiskā cīņa starp Latvijas Komunistiskās partijas eliti un latviešu progresīvo inteliģenci. Pētījumā raksturota vispārējā situācija Latvijā pirms 1991. gada janvāra, Latvijas Tautas frontes frakcijas izveide un tās ietekme Latvijas politiskajos procesos, kā ar…

Latvijas ārolitikaLatvijas iekšpolitikaLatvijas Tautas fronte1991. gada janvārisVēsture
researchProduct

O-Serogrouping and surface components ofAeromonas hydrophilaandAeromonas jandaeipathogenic for eels

1994

The relationship between virulence, O-serogroup, and some cell-surface features (self-pelleting [SP] and precipitation after boiling [PAB], profile of lipopolysaccharides [LPSs] and outer membrane proteins [OMPs]) was investigated in strains of the pathogenic species Aeromonas hydrophila and A. jandaei isolated from eels. Virulent strains of A. hydrophila reacted mostly with O:19 antiserum, and those of A. jandaei reacted with O:4, O:11, O:15 and O:29 antisera (Guinée and Jansen system). Regarding the PAB and LPS profiles two groups could be distinguished; (i) five PAB+ strains of serotype O:19 that possessed a homogeneous O polysaccharide side chain and (ii) thirteen PAB- strains antigenic…

LipopolysaccharidesSerotypeVirulenceBiologyMicrobiologyMicrobiologyVibrionaceaeGeneticsAnimalsSerotypingMolecular BiologyAntiserumEelsVirulenceCell MembranePolysaccharides BacterialO Antigensbiology.organism_classificationAntibodies BacterialAeromonas hydrophilaAeromonas hydrophilaPhenotypeAeromonasAeromonas jandaeiAeromonasBacteriaBacterial Outer Membrane ProteinsFEMS Microbiology Letters
researchProduct

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

2015

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10−8) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine–cytokine pathways, for which relevant therapies exist.

Liver CirrhosisGenetics and Molecular Biology (all)pathogenesirisk assessment EMTREE medical terms: Articlegenetic associationgenotypeEMTREE drug terms: chemokine receptor CCR6genetic riskBiochemistrymeta-analysiprimary biliary cirrhosichemokine receptor CCR6 [EMTREE drug terms]single nucleotide polymorphismgenetic variabilityArticle [risk assessment EMTREE medical terms]Liver Cirrhosis BiliarypathogenesisBiliaryChemistry (all)STAT protein GEOBASE Subject Index: disease treatmentcohort analysisgenome wide meta analysis PBCsignal transductiongene locuscohort analysiCBPArticle*Physics and Astronomy (all)macrophage inflammatory protein 3alphaHumanscontrolled studyhumaninterleukin 27genomeBiochemistry Genetics and Molecular Biology (all)meta analysiinterleukin 12p40EMTREE drug terms: chemokine receptor CCR6; interleukin 12; interleukin 12p40; interleukin 27; Janus kinase; macrophage inflammatory protein 3alpha; STAT protein GEOBASE Subject Index: disease treatment; genome; meta-analysis; pathogen; risk assessment EMTREE medical terms: Article; cohort analysis; controlled study; gene locus; genetic association; genetic predisposition; genetic risk; genetic variability; genotype; human; major clinical study; meta analysis; pathogenesis; primary biliary cirrhosis; signal transduction; single nucleotide polymorphismmajor clinical studyprimary biliary cirrhosismeta-analysisdisease treatment [STAT protein GEOBASE Subject Index]Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Humans; Liver Cirrhosis; Biliary; Genome-Wide Association Study; Biochemistry; Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)gene locuinterleukin 12genetic predispositionJanus kinasepathogenmeta analysisHumans; Liver Cirrhosis Biliary; Genome-Wide Association Study; Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Genome-Wide Association Study
researchProduct

Presence of calreticulin mutations in JAK2-negative polycythemia vera

2014

Abstract Calreticulin (CALR) mutations have recently been reported in JAK2- and MPL-negative Myeloproliferative Neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).The clinical course of sporadic CALR-mutated patients seems to be more indolent than that of JAK2-mutated patients. In contrast, no CALR mutation has been found in the 647 published cases of Polycythemia Vera (PV) patients tested. Consequently, CALR mutations were considered exclusive to JAK2 and MPL mutations. Since 98% of PV patients harbor a JAK2 mutation (mostly the V617F mutation in exon 14 and more rarely, in exon 12), the absence of CALR mutations in PV seemed logical. Here, we desc…

MaleErythrocytesMESH: Thrombocytosismedicine.disease_causeMESH: Polycythemia VeraBiochemistryMESH: Janus Kinase 2MESH: GenotypeHemoglobinsMESH: Aged 80 and overPolycythemia verahemic and lymphatic diseasesPolycythemia VeraMESH: HeterozygoteAged 80 and overThrombocytosisMESH: AgedMutation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyJanus kinase 2biologyMESH: ErythrocytesExonsHematologyLeukemiaMESH: HemoglobinsMESH: Primary MyelofibrosisThrombocythemia EssentialHeterozygoteMESH: MutationGenotypeMESH: CalreticulinImmunologyContext (language use)medicineHumansMyelofibrosisAllelesAgedMESH: HumansEssential thrombocythemiabusiness.industryMESH: AllelesCell BiologyJanus Kinase 2medicine.diseaseMESH: MalePrimary MyelofibrosisMESH: Gene DeletionMutationImmunologybiology.proteinCancer researchMESH: Thrombocythemia EssentialCalreticulinMESH: ExonsbusinessCalreticulinGene Deletion[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBlood
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus.

2020

An increased calcitonin serum level is suggestive of a medullary thyroid cancer (MTC), but is not pathognomonic. The possibility of false positives or other calcitonin-secreting neuroendocrine neoplasms (NENs) should be considered. Serum calcitonin levels are generally assessed by immunoradiometric and chemiluminescent assays with high sensitivity and specificity; however, slightly moderately elevated levels could be attributable to various confounding factors. Calcitonin values &gt;100 pg/mL are strongly suspicious of malignancy, whereas in patients with moderately elevated values (10–100 pg/mL) a stimulation test may be applied to improve diagnostic accuracy. Although the standard protoco…

MalediagnosisEndocrinology Diabetes and Metabolismbiomarkers; tumor; calcitonin; calcitonin gene-related peptide; carcinoma neuroendocrine; diagnosis differential; endocrine gland neoplasms; false positive reactions; female; humans; janus kinases; male; middle aged; reference values; sensitivity and specificity; thyroid neoplasmscarcinoma0302 clinical medicineEndocrinologyReference ValuehumansEndocrine Gland NeoplasmThyroidMedullary thyroid cancerGeneral MedicineFalse Positive Reactionreference valuesMiddle Agedmedicine.anatomical_structure030220 oncology & carcinogenesisFemalehormones hormone substitutes and hormone antagonistsHumanThyroid nodulesCalcitoninmedicine.medical_specialtytumordifferentialCalcitonin Gene-Related Peptide030209 endocrinology & metabolismNeuroendocrinologySensitivity and SpecificityDiagnosis Differential03 medical and health sciencesInternal medicinemedicineBiomarkers TumorneuroendocrineThyroid NeoplasmsCalcitonin Measurementbusiness.industryfalse positive reactionsbiomarkersCalcitonin secretionmedicine.diseaseCarcinoma NeuroendocrineEndocrinologyCalcitoninjanus kinasesJanus KinaseDifferential diagnosisendocrine gland neoplasmsbusiness
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct